-
31.发明公开면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물 审中-实审包含二甲双胍的组合物用于预防或治疗由免疫抑制剂诱导的线粒体疾病和免疫疾病
公开(公告)号：KR1020170106283A
公开(公告)日：2017-09-20
申请号：KR1020170117455
申请日：2017-09-13
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K31/436
CPC classification number: A61K31/155 , A61K31/436
Abstract: 본발명은면역억제제로유발되는미토콘드리아질환및 면역질환의예방또는치료를위한메트포민을포함하는조성물에대한것으로, 보다상세하게는면역억제제로유발되는미토콘드리아질환치료를위한메트포민을포함하는조성물, 메트포민과라파마이신표적억제제(mTOR inhibitor)인면역억제제를유효성분으로포함하는면역질환의예방또는치료용약학적조성물및 메트포민과포유류라파마이신표적억제제를구성요소로포함하며이들을동시에또는개별적으로또는정해진순서로투여하는것을특징으로하는면역질환의예방또는치료용약학적복합제제에관한것이다. 본발명의조성물은기존면역억제제의부작용으로생기는미토콘드리아의기능손상을효과적으로완화하고면역억제치료효과는더욱향상되어, 면역억제가필요한이식거부반응, 자가면역질환, 염증성질환등을예방하거나치료하는데유용하게이용될수 있다.
Abstract translation: 包括用于由是，更具体地，所述组合物的免疫抑制剂，其包括用于由免疫抑制剂，二甲双胍引起的预防或治疗线粒体疾病和自身免疫性疾病的二甲双胍和引起线粒体疾病二甲双胍本发明组合物 在预防或治疗药物的医药组合物和二甲双胍和哺乳动物拉帕施用雷帕霉素靶抑制剂（mTOR抑制剂）包括雷帕霉素靶抑制剂成分，并且这些同时或分别或免疫疾病，包括人掩模台抑制剂作为活性成分的特定顺序 以及预防或治疗免疫疾病的方法。 本发明的组合物被有效地减轻由于作为现有的免疫抑制剂的副作用线粒体功能的损害，并且进一步增强了免疫抑制的治疗效果，移植排斥需要免疫抑制的，自身免疫性疾病，用于预防或治疗炎性疾病等有用的 它可以被使用。
-
公开(公告)号：KR101760510B1
公开(公告)日：2017-07-21
申请号：KR1020150179374
申请日：2015-12-15
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/155 , A61K38/13 , A61K31/436 , A61K9/16 , A61K9/20 , A61K47/36
CPC classification number: A61K31/155 , A61K31/436 , A61K38/13
Abstract: 본발명은메트포민(metformin)을포함하는면역억제제로인한신장독성완화용조성물및 이를포함하는면역질환예방또는치료용조성물에관한것으로, 보다상세하게는메트포민을유효성분으로포함하는면역억제제로유발된신장독성감소용조성물, 메트포민과칼시뉴린억제제(calcineurin inhibitor)를유효성분으로포함하는면역질환의예방또는치료용약학적조성물및 메트포민과칼시뉴린억제제를구성요소로포함하며이들을동시에, 개별적으로또는정해진순서로투여하는것을특징으로하는면역질환의예방또는치료용약학적복합제제에관한것이다. 본발명의조성물은기존면역억제제의부작용으로생기는신장기능저하를효과적으로완화하여면역억제가필요한질병의치료효과를높이는데유용하게이용될수 있으며, 더나아가기존의면역억제제와메트포민을병용투여하는다양한방법을제시하여기존면역억제제의신장독성부작용은줄이고, 면역억제또는면역조절효과는극대화함으로써, 장기이식거부반응, 자가면역질환, 염증성질환등을예방하거나치료하는데유용하게이용될수 있다.
-
公开(公告)号：KR101620153B1
公开(公告)日：2016-05-12
申请号：KR1020140000937
申请日：2014-01-03
Applicant: 가톨릭대학교 산학협력단
IPC: A61K36/234 , A61P19/02 , A61P19/00
Abstract: 본발명은갯방풍추출물을유효성분으로포함하는관절염또는골다공증의예방또는치료를목적으로한 약학조성물에관한것이다. 본발명에따른갯방풍추출물은염증성사이토카인 IL-17, IL-6 또는 TNF-의활성을감소또는억제시키는활성이우수하고, 파골세포분화를감소시키는효과가우수하여관절염또는골다공증의예방또는치료할수 있는조성물로유용하게사용할수 있다.또한, 세포독성이일어나지않으며, 약물에대한독성및 부작용도없어장기간복용시에도안심하고사용할수 있으며, 체내에서도안정한효과가있다.
-
公开(公告)号：KR101490586B1
公开(公告)日：2015-02-05
申请号：KR1020130041359
申请日：2013-04-16
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61K38/17 , C12N15/63 , C12N15/12
Abstract: 본 발명은 Rcan3를 활성화시키는 항산화제의 신규 용도에 관한 것으로, 자세하게는 Rcan3 유전자 발현을 증가시키는 활성을 갖는 항산화제; 항산화제를 세포에 처리하는 단계를 포함하는 Rcan3 유전자 발현을 증가시키는 방법; 및 Rcan3 단백질을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 항산화제는 Rcan3의 유전자 발현을 효과적으로 증대시킬 수 있는 신규 용도를 가지므로, 이를 이용하여 Rcan3 단백질을 용이하게 증폭시킬 수 있고, 이렇게 증폭된 Rcan3 단백질은 칼시뉴린 경로를 억제할 수 있어 면역질환을 예방 또는 치료할 수 있는 면역 억제제로서 유용하게 사용할 수 있다. 또한, 상기 Rcan3 단백질은 천연 단백질로서 독성 및 부작용도 없어 장기간 안심하고 사용할 수 있으며, 체내에 대해 안정한 효과가 있다.
-
公开(公告)号：KR1020140089315A
公开(公告)日：2014-07-14
申请号：KR1020140000937
申请日：2014-01-03
Applicant: 가톨릭대학교 산학협력단
IPC: A61K36/234 , A61P19/02 , A61P19/00
Abstract: The present invention relates to a composition for preventing or treating arthritis or osteoporosis comprising extract of glehnia littoralis as an active ingredient. According to the present invention, the extract of glehnia littoralis has excellent activity to reduce or inhibit activity of inflammatory cytokines such as IL-17, IL-6, or TNF-, and has an improved effect of reducing osteoclast differentiation, thereby being used as a composition for preventing or treating arthritis or osteoporosis. Also, the extract of glehnia littoralis does not cause cytotoxicity, has no toxicity and side effects to the drug, thereby being safely used even in long-term use, and can be stable in vivo.
Abstract translation: 本发明涉及一种用于预防或治疗关节炎或骨质疏松症的组合物，其包含小檗碱提取物作为活性成分。 根据本发明，小叶提取物具有优异的降低或抑制IL-17，IL-6或TNF-α等炎性细胞因子活性的活性，具有改善破骨细胞分化的作用，从而被用作 用于预防或治疗关节炎或骨质疏松症的组合物。 而且，小檗提取物不会引起细胞毒性，对药物无毒副作用，即使长期使用也能安全使用，可在体内稳定。
-
Patent Agency Ranking
公开(公告)号：KR1020130126554A
公开(公告)日：2013-11-20
申请号：KR1020130053814
申请日：2013-05-13
Applicant: 가톨릭대학교 산학협력단
IPC: G01N33/53 , G01N33/563 , C12Q1/02
CPC classification number: G01N33/5091 , G01N33/56966 , G01N33/56972 , G01N33/56977 , G01N33/6866 , G01N33/6869 , G01N2333/57 , G01N2800/245
Abstract: The present invention relates to a monitoring kit for an immune status after transplantation, and more particularly, a monitoring kit for the immune status after the transplantation, containing materials for measuring Th17 cells, Treg cells, Th1 cells, CD8EM(CD8 effect memory) IFN-γ-positive cells, and CD8CM(CD8 central memory) IFN-γ-positive cells, and a monitoring method for the immune status of the individual receiving the transplantation including a step of measuring the cell number of Th17 cells, Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the peripheral blood of an object receiving the transplantation, and a step for calculating each cell number ratio of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells against the number of Th17 cells by dividing the measured values of cell numbers of Treg cells, Th1 cells, CD8EM IFN-γ-positive cells, and CD8CM IFN-γ-positive cells with the measured value of the cell number of Th17 cells. The monitoring method and kit for the immune status of the individual receiving the transplantation provided by the present invention are capable of determining the immune status with ease and accuracy, thereby reducing the excessive use of an immunosuppressant prescribed after transplantation and managing the immune status of each patient. [Reference numerals] (AA,EE,II,MM,QQ,UU) Normally take CNI (100% taking);(BB,DD,FF,HH,JJ,LL,NN,PP,RR,TT,VV,XX) Reduce CNI by 25% (75% taking);(CC,GG,KK,OO,SS,WW) Reduce CNI 50% (50% taking)
Abstract translation: 本发明涉及用于移植后免疫状态的监测试剂盒，更具体地，涉及用于移植后免疫状态的监测试剂盒，其包含用于测量Th17细胞，Treg细胞，Th1细胞，CD8EM（CD8效应记忆）IFN - γ阳性细胞和CD8CM（CD8中枢记忆）IFN-γ阳性细胞，以及接受移植的个体的免疫状态的监测方法，包括测量Th17细胞，Treg细胞的细胞数的步骤 ，Th1细胞，CD8EM IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞对抗接受移植的对象的外周血，以及计算Treg细胞，Th1细胞，CD8EM的每个细胞数比例的步骤 通过将Treg细胞，Th1细胞，CD8EM IFN-γ阳性细胞和CD8CM IFN的细胞数量的测量值除以相对于Th17细胞数量的IFN-γ阳性细胞和CD8CM IFN-γ阳性细胞 - ＆伽马; -posi T细胞与Th17细胞的细胞数量的测量值。 本发明提供的接受移植的个体的免疫状态的监测方法和试剂盒能够容易且准确地测定免疫状态，从而减少移植后规定的免疫抑制剂的过度使用，并且管理每种免疫抑制剂的免疫状态 患者。 （AA，EE，II，MM，QQ，UU）通常采用CNI（100％服用）;（BB，DD，FF，HH，JJ，LL，NN，PP，RR，TT，VV，XX ）将CNI降低25％（75％服用）;（CC，GG，KK，OO，SS，WW）减少CNI 50％（50％服用）
-
公开(公告)号：KR101144563B1
公开(公告)日：2012-05-11
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
-
公开(公告)号：KR1020110137588A
公开(公告)日：2011-12-23
申请号：KR1020100057601
申请日：2010-06-17
Applicant: 에이치 엘 지노믹스(주) , 가톨릭대학교 산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing Vitis vinifera seed extract and pharmaceutically acceptable carrier is provided to prevent and treat obesity. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Vitis vinifera seed extract and pharmaceutically acceptable carrier. The extract has 80-130 of procyanidolic value(PCV) and contains less than 30% of (+)catechin and (-) epicatechin and 95-105% of proanthocyanidin content. A method for preparing the extract comprises: a step of mixing pulverized Vitis vinifera seed and a mixture solvent of acetone and water and isolating at room temperature; a step of filtering the extract and distilling the filtered liquid to remove acetone; a step of saturating sodium chloride and filtering; a step of extracting the liquid with ethyl acetate and concentrating; and a step of adding chloroform and filtering.
Abstract translation: 目的：提供含有葡萄籽提取物和药学上可接受的载体的药物组合物以预防和治疗肥胖症。 构成：用于预防或治疗肥胖症的药物组合物含有葡萄种子提取物和药学上可接受的载体。 提取物具有80-130原花青素值（PCV），并且含有少于30％的（+）儿茶素和（ - ）表儿茶素和95-105％的原花色素含量。 一种制备提取物的方法包括：将经粉碎的葡萄种子和丙酮和水的混合溶剂混合并在室温下分离的步骤; 过滤提取物并蒸馏过滤的液体以除去丙酮的步骤; 使氯化钠饱和并过滤的步骤; 用乙酸乙酯萃取液体并浓缩的步骤; 并加入氯仿和过滤步骤。
-
公开(公告)号：KR1020110121086A
公开(公告)日：2011-11-07
申请号：KR1020100040518
申请日：2010-04-30
Applicant: 가톨릭대학교 산학협력단
IPC: A01K67/027
CPC classification number: A01K67/027 , A01K2207/25 , A01K2227/105 , A01K2267/03
Abstract: PURPOSE: An arthritis mouse animal model and a manufacturing method thereof are provided to more seriously a symptom of arthritis. CONSTITUTION: A manufacturing method of an arthritis mouse animal model comprises: a step of inducing obesity by feeding high caloric fodder to mouse; and a step of causing arthritis by ministering collagen in the mouse. In the collagen ministering step, collagen is inoculated firstly, a mouse is bred for a specified period, and collagen is inoculated secondly. In the first inoculation, mixture solution of collagen and complete freud's adjuvant is administered. In the second inoculation, mixture solution of collagen and incomplete freud's adjuvant is administered.
Abstract translation: 目的：提供关节炎小鼠动物模型及其制造方法，以更严重地关注关节炎的症状。 构成：关节炎小鼠动物模型的制造方法包括：通过向小鼠喂食高热量饲料来诱导肥胖的步骤; 以及通过在小鼠中服用胶原来引起关节炎的步骤。 在胶原蛋白传代步骤中，首先接种胶原，将小鼠育种一段指定的时间，然后接种胶原蛋白。 在第一次接种中，施用胶原蛋白和完全弗氏佐剂的混合溶液。 在第二次接种中，施用胶原蛋白和不完全弗氏佐剂的混合溶液。
-
公开(公告)号：KR1020210043796A
公开(公告)日：2021-04-22
申请号：KR1020190126394
申请日：2019-10-11
Applicant: 가톨릭대학교 산학협력단 , 주식회사 비피도
IPC: C12N1/20 , A23L33/135 , A61P19/02 , C12R1/01
Abstract: 본발명은비피도박테리움슈도카테눌라툼 (Bifidobacterium pseudocatenulatum) C-RAPO 균주및 이를포함하는류마티스관절염개선용, 치료용또는예방용조성물에관한것으로, 본발명에서새롭게분리한비피도박테리움슈도카테눌라툼 (Bifidobacteriumpseudocatenulatum) C-RAPO는류마티스관절염치료효과가뛰어나므로류마티스관절염치료제또는류마티스관절염개선용프로바이오틱스소재로유용하게이용될수 있다.
-
-
-
-
-
-
-
-
-
Search Results
78
records
(took 0.034 seconds)
